Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression

Prostate

Volumn 73, Issue 16, 2013, Pages 1738-1746

  Ricci, Estelle ^a   Mattei, Eve ^b   Dumontet, Charles ^b   Eaton, Colby L ^c   Hamdy, Freddy ^d   Van Der Pluije, Gabri ^e   Cecchini, Marco ^f   Thalmann, George ^f   Clezardin, Philippe ^g   Colombel, Marc ^a,g  

^a UNIVERSITÉ LYON 1   (France)

^b Groupement Hospitalier Est   (France)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF BERN   (Switzerland)

^g INSERM   (France)

Author keywords

2 integrin subunit; 6 integrin subunit; bone metastasis; c Met; disseminated tumor cells; prostate cancer

Indexed keywords

ALPHA2 INTEGRIN; ALPHA6 INTEGRIN; CD45 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; SCATTER FACTOR RECEPTOR;

ARTICLE; BONE MARROW; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER STEM CELL; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CAUSE OF DEATH; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN CELL; LEUKOCYTE; LIMIT OF DETECTION; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION;

Α-2 INTEGRIN SUBUNIT; Α-6 INTEGRIN SUBUNIT; BONE METASTASIS; C-MET; DISSEMINATED TUMOR CELLS; PROSTATE CANCER;

ADULT; ANTIGENS, CD45; BIOPSY; BONE MARROW; BONE NEOPLASMS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; HUMANS; INTEGRIN ALPHA2; INTEGRIN ALPHA6; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84886952487     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22689     Document Type: Article

References (27)

1. Karim-Kos HE, de Vries Soerjomataram I, Lemmens V, Siesling S, Coebergh JW,. Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44: 1345-1389.
2. Bianco FJ Jr, Scardino PT, Eastham JA,. Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function ("trifecta" ). Urology 2005; 66: 83-94.
3. Pantel K, Alix-Panabieres C, Riethdorf S,. Cancer micrometastases. Nat Rev Clin Oncol 2009; 6: 339-351.
4. Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, Vessella RL,. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 2009; 15: 677-683.
5. Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H, Bertz S, Harzmann R, Klein CA,. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 2009; 27: 1549-1556.
6. Gil-Diez de MS, Salomon L, Colombel M, Abbou CC, Bellot J, Thiery JP, Radvanyi F, Van der Kwast TH, Chopin DK,. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol 1998; 29: 1005-1012.
7. Schalken JA, van Leenders G,. Cellular and molecular biology of the prostate: Stem cell biology. Urology 2003; 62 (5 Suppl 1): 11-20.
8. Miki J, Furusato B, Li H, Guy Y, Takahashi H, Egawa S, Sesterhenn IA, McLeaod DG, Srivastava S, Rhim JS,. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007; 67: 3153-3161.
9. Guzman-Ramirez N, Voller M, Wetterwald A, Germann M, Cross NA, Rentsch CA, Schalken J, Thalmann GN, Cecchini MG,. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 2009; 69: 1683-1693.
10. Burger PE, Gupta R, Xiong X, Ontiveros CS, Salm SN, Moscatelli D, Wilson EL,. High aldehyde dehydrogenase activity: A novel functional marker of murine prostate stem/progenitor cells. Stem Cells 2009; 27: 2220-2228.
11. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT,. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117: 3539-3545.
12. Colombel M, Eaton CL, Hamdy F, Ricci E, Van der Pluijm G, Cecchini M, Mege Lechevallier F, Clezardin P, Thalmann G,. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate 2012; 72: 713-720.
13. Van der Pol MA, Broxterman HJ, Westra G, Ossenkoppele GJ, Schuurhuis GJ,. Novel multiparameter flow cytometry assay using Syto16 for the simultaneous detection of early apoptosis and apoptosis-corrected P-glycoprotein function in clinical samples. Cytometry B Clin Cytom 2003; 55: 14-21.
14. Bonkhoff H, Remberger K,. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 1996; 28: 98-106.
15. Gu G, Yuan J, Wills M, Kasper S,. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007; 67: 4807-4815.
16. Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein Hahm SA, Haider M, Head CS, Reiter RE, Rubin MA, Witte ON,. Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate 2010; 70: 491-501.
17. Lawson DA, Xin L, Lukacs RU, Cheng D, Witte ON,. Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci USA 2007; 104: 181-186.
18. Kasper S,. Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev 2008; 4: 19-201.
19. Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Watterwald A, Lippitt J, Rehman I, Hamdy F, Thalman G,. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate 2010; 70: 875-882.
20. Tantivejkul K, Kalikin LM, Pienta KJ,. Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 2004; 91: 706-717.
21. Hall CL, Dai J, van Golen KL, Keller ET, Long MW,. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 2006; 66: 8648-8654.
22. Miller MC, Doyle GV, Terstappen LW,. Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010; 2010: article id 617421.
23. Hayes DF, Smerage JB,. Circulating tumor cells. Prog Mol Biol Transl Sci 2010; 95: 95-112.
24. Goodman OB Jr, Fink LM, Symanowski JT, Wong B, Grobaski B, Pomerantz D, Ma Y, Ward DC, Vogelzang NJ,. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomarkers Prev 2009; 18: 1904-1913.
25. Shiozawa Y, Pienta KJ, Taichman RS,. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res 2011; 17: 5553-5558.
26. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold Marcoù PK, George DJ, Garcia-Blanco MA,. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 2011; 9: 997-1007.
27. Van der Horst G, van den Hoogen C, Buijs JT, Cheung H, Bloys H, Pelger RC, Lorenzon G, Heckmann B, Feyen J, Pujuguet P, Blanque R, Clément- Lacroix P, Van der Pluijm G,. Targeting of alpha(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. Neoplasia 2011; 13: 516-525.